Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 10(2023), 5 vom: 15. Mai, Seite ofad205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sweeney, Daniel A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 15.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofad205 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357091337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357091337 | ||
| 003 | DE-627 | ||
| 005 | 20231226071838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofad205 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357091337 | ||
| 035 | |a (NLM)37206623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sweeney, Daniel A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a baricitinib | |
| 650 | 4 | |a secondary infections | |
| 700 | 1 | |a Tuyishimire, Bonifride |e verfasserin |4 aut | |
| 700 | 1 | |a Ahuja, Neera |e verfasserin |4 aut | |
| 700 | 1 | |a Beigel, John H |e verfasserin |4 aut | |
| 700 | 1 | |a Beresnev, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Cantos, Valeria D |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Jose G |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Stuart H |e verfasserin |4 aut | |
| 700 | 1 | |a Cross, Kaitlyn |e verfasserin |4 aut | |
| 700 | 1 | |a Dodd, Lori E |e verfasserin |4 aut | |
| 700 | 1 | |a Erdmann, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Ghazaryan, Varduhi |e verfasserin |4 aut | |
| 700 | 1 | |a George, Sarah L |e verfasserin |4 aut | |
| 700 | 1 | |a Grimes, Kevin A |e verfasserin |4 aut | |
| 700 | 1 | |a Hynes, Noreen A |e verfasserin |4 aut | |
| 700 | 1 | |a Julian, Kathleen G |e verfasserin |4 aut | |
| 700 | 1 | |a Kandiah, Sheetal |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hannah Jang |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, Corri B |e verfasserin |4 aut | |
| 700 | 1 | |a Lindholm, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Lye, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Maves, Ryan C |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Myoung-Don |e verfasserin |4 aut | |
| 700 | 1 | |a Paules, Catharine |e verfasserin |4 aut | |
| 700 | 1 | |a Rapaka, Rekha R |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Willam R |e verfasserin |4 aut | |
| 700 | 1 | |a Tomashek, Kay M |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfe, Cameron R |e verfasserin |4 aut | |
| 700 | 1 | |a Kalil, Andre C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 10(2023), 5 vom: 15. Mai, Seite ofad205 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:5 |g day:15 |g month:05 |g pages:ofad205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofad205 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 5 |b 15 |c 05 |h ofad205 | ||